Vertex Pharma Earnings: Net Income and Revenue Drop, Drags Shares

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. However the net income and revenue declined. Shares are down 2.13%.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

Vertex Pharmaceuticals Incorporated Earnings Cheat Sheet

Results: Net income decreased -94.33% to $9 million (4 cents per diluted share) in the quarter versus a net gain of $158.63 million in the year-earlier quarter.

Revenue: Decreased 40.71% to $334 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Vertex Pharmaceuticals Incorporated reported adjusted net income of 4 cents per share. It beat the average revenue estimate of $318.5 million.

Quoting Management: “Entering 2013, we are committed to advancing key development programs and to maintaining financial strength to position the company for sustainable long-term growth,” said Jeffrey Leiden, M.D., Ph.D., Chair, President and CEO of Vertex…

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Premium Newsletters

Stock Investor Cheat Sheet

Stock Investor Cheat Sheet®

The ultimate Cheat Sheet for finding winning stock picks.
Learn More

Gold & Silver Newsletter

Gold & Silver

Don't miss one of the biggest bull markets in history! Covers Gold, Silver, Gold & Silver stocks, and miners.
Learn More

Commodities Premium Newsletter

Commodities Premium

There's always a bull market in some sector! Find the best opportunities in commodities.
Learn more

ETF Investing

ETF Investing

At last, a trading system that buys the right ETFs at the right time, time after time!
Learn more

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business